The Impact of Fecal Microbiota Transplantation as an Immunomodulation on the Risk Reduction of COVID-19 Disease Progression With Escalating Cytokine Storm and Inflammatory Parameters

NCT ID: NCT04824222

Last Updated: 2021-04-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 366 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-30
• Study Completion Date: 2022-12-31

Brief Summary

The gut microbiota provides an intestinal biological barrier against pathogens and has a pivotal role in the maintenance of intestinal homeostasis and modulation of the host immune system. The gut microbiota in a dysbiotic state has increasingly been implicated in the pathogenesis and progression of numerous diseases. However, whether dysbiosis reflects changes caused by the disease itself, or should be considered as a driving step in the pathogenesis, is not always understood. Dysbiosis results in the disturbance of several metabolic pathways that influence immunological and mechanical processes both in and outside the intestine, and it impairs colonization resistance. These processes may be reverted by fecal microbiota transplantation (FMT). FMT is a type of treatment that relies on transferring the microbiota that targets and corrects intestinal dysbiosis. FMT is based on collecting stool from healthy donors and - after preparation - administering the material to an individual with a specific disease.

In summary, a subset of the symptoms associated with COVID-19 during the initial phase are intestinal complications, such as vomiting or diarrhea. Detecting these symptoms might not only lead to slowdown in transmission but also open the door to novel treatments that could reduce the severity of COVID-19.There is a positive correlation between severity of patient condition and level of proinflammatory cytokines (cytokine storm) in group of patients with COVID 19. Though numerous studies have been published on FMT for the treatment of certain diseases, there are only scarce studies on FMT for the treatment of SARS-CoV-2. Antiviral mechanism depended on the gut-lung axis was intimately proved in case of flu virus. The same dependency is observed in SARS CoV2 as well. That seems, good condition of intestinal microbiota could impact on antiviral effects and inhibits replication of virus. This leads to inhibit progress of inflammatory process in lung tissue. Silencing of inflammatory process through reestablish right influence of gut-lung axis could be fundamental meaning in arresting of cytokines storm and development of ARDS in patients with COVID-19.

The scientist rationale definitely argue a clear need to studies of gut wellbeing in COVID 19 and using FMT to reduce development of COVID 19. According to our knowledge FeMToCOVID will be the first clinical trial with using of FMT in COVID 19. We postulate FMT in the beginning of cytokine storm during CIVUD-19 may act as an immunomodulation and stop the progression of the disease.

Conditions

Covid19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

A - SOC+IMP

The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).

Group Type: EXPERIMENTAL

Human fecal microbiota, MBiotix HBI

Intervention Type: DRUG

The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).

SOC

Intervention Type: DRUG

The standard COVID 19 pharmacological treatment

B - SOC+placebo

Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)

SOC

Intervention Type: DRUG

The standard COVID 19 pharmacological treatment

Interventions

Human fecal microbiota, MBiotix HBI

The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).

Intervention Type: DRUG

Placebo

Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)

Intervention Type: DRUG

SOC

The standard COVID 19 pharmacological treatment

Intervention Type: DRUG

Other Intervention Names

MBiotix HBI

Eligibility Criteria

Inclusion Criteria

1. Subject has signed Informed Consent Form and is able to understand the purpose and procedures required for the study and is willing to participate in the study.

2. Male or female in aged 18 and older.

3. Expected survival time, not taking into account SARSCoV2 infection, is at least 6 months.

4. Diagnosis of COVID 19 disease confirmed by SARSCoV2 PCR test (the validity of test 7 days before the start of screening).

5. Hospitalization due to COVID 19 disease or disease with accompanied COVID 19.

6. Any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in COVID 19 Performance Status Scale).

7. Initially escalated inflammatory process, defined as compliance at least 2 parameters from group "A", during 24 hours before including patient to the study or at least one parameter from group "B".

Group "A":

1. Plasma Amyloid A to lymphocyte count Ratio is greater than 100 (SAA/L>100)

2. SAA >100mg/l

3. Leukocytosis (WBC) over 10 k/ul with absolute lymphopenia under 1,0 k/ul

4. CRP >100 mg/l and absolute lymphopenia

5. IL-6 >25 pg/ml

6. Inflammatory changes in lung assessed based on high resolution computed tomography (HRCT) at least 2 points in COVID-CT scale.

Group "B":

Inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests:

1. increase of plasma Amyloid A (SAA) to lymphocyte count ratio (SAA/L) by at least 25% compared to initial result (at least a day before)

2. increase of SAA concentration by at least 25% compared to initial result (at least a day before)

3. decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago)

4. increase of CRP by at least 50% compared to initial result (at least a day before)

5. increase of IL-6 by at least 25% compared to initial result (at least a day before)

6. progression of lung changes in CT compared to initial picture (assessed in COVID-CT scale; at least a day before)

7. decline of PaO2/FiO2 by at least 100 mmHg, but not lower than 200 mmHg

Exclusion Criteria

1. Age < 18 years old.

2. Inability to obtain Informed Consent.

3. Patient's impaired consciousness in opinion of investigator.

4. Swallowing difficulties before SARS-CoV 2 infection or related to SASRS-CoV 2 infection (eg. Caused by dyspnea).

5. Severe food allergy.

6. At least 7 points in COVID-19 Performance Status.

7. Patients, who need blood transfusion in the day of study inclusion.

8. Significant intestinal passage disturbance, eg. bowel irritation, bowel obstruction, after bowel or stomach resection etc. diagnosed before COVID 19 diagnosis.

9. Stoma, perforation or abscess located in gastrointestinal tract area in the past.

10. Clinical significant systemic or localised infections, other than COVID 19, eg. lung abscess, pleural abscess, hepatitis, tuberculosis, sepsis ect.

11. Severe cardiac failure (NYHA III or more) before COVID 19 diagnosis.

12. Significant higher liver parameters: alanine aminotransferase or aspartate aminotransferase > 500 U/l.

13. Important primary or secondary immune dysfunction - eg. AIDS, severe neutropenia (neutrophiles < 0,5k/ul), inborn immunodeficiency, myelosuppression after chemotherapy etc.

14. Necessity of systemic antibiotic therapy in time of screening or inclusion to study.

15. Female in reproductive age with positive pregnancy test during screening.

16. Breast-feeding female.

17. Female after menopause:

1. After an ovariohysterectomy

2. Confirmed ovaries inactivity

3. Menopause defined as at least 12 months after last menstruation or FSH > 40 IU/l.

18. Patients in severe systemic condition, it means comply at least on of the following:

1. Need mechanical ventilation

2. Ratio of PaO2/FiO2 lower than 200 mmHg

3. Need the vasopressors, because of the shock

4. Unconscious patients

19. Taking any experimental medication, except remdesivir and convalescents plasma or medication in other clinical trial within 30 days or if the time is shorter than 5 half-lifes, depended which time will be longer before day "0"

20. Human Immunodeficiency Virus infection, active hepatitis B or C virus infection, fresh infection of CMV, EBV or influenza virus.

21. The co-existence of severe systemic disorder, which in opinion of investigator can endanger significant medication interactions or inability to follow protocol

22. Lactose intolerance.

23. The inability to administration testing capsule.

24. Other, conditions unexpected in protocol, which in opinion of investigator considers excluding from study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Human Biome Institute S.A.

INDUSTRY

Sponsor Role: collaborator

Medical University of Warsaw

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jarosław Biliński, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Warsaw

Central Contacts

Jarosław Biliński, MD, PhD

Role: CONTACT

jaroslaw.bilinski@gmail.com

0048225992818

Other Identifiers

2020-003915-84

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

FeMToCOVID

Identifier Type: -

Identifier Source: org_study_id